{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T06:15:18Z","timestamp":1783318518335,"version":"3.54.6"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017501","name":"Science-Health Joint Medical Scientific Research Project of Chongqing","doi-asserted-by":"publisher","award":["2025ZYYB021"],"award-info":[{"award-number":["2025ZYYB021"]}],"id":[{"id":"10.13039\/100017501","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017501","name":"Science-Health Joint Medical Scientific Research Project of Chongqing","doi-asserted-by":"publisher","award":["2025GGXM003"],"award-info":[{"award-number":["2025GGXM003"]}],"id":[{"id":"10.13039\/100017501","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Biologic switching is common in clinical practice for patients with moderate-to-severe plaque psoriasis who fail secukinumab therapy. There is limited real-world evidence comparing different switching strategies, especially within-class vs. across-class approaches.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the effectiveness and safety of switching to ixekizumab, guselkumab, or ustekinumab in patients with moderate-to-severe plaque psoriasis who failed secukinumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this retrospective cohort study, 59 patients who switched from secukinumab to ixekizumab (\n                      <jats:italic>n<\/jats:italic>\n                      = 21), guselkumab (\n                      <jats:italic>n<\/jats:italic>\n                      = 32), or ustekinumab (\n                      <jats:italic>n<\/jats:italic>\n                      = 6) between January 2021 and June 2025 were analyzed. Primary endpoints were Psoriasis Area and Severity Index (PASI) 75, PASI 90, and PASI 100 response rates at weeks 12, 24, and 52. Subgroup analyses were performed by reason for switching (primary failure vs. secondary failure). Missing data were handled using non-responder imputation (NRI).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Ixekizumab demonstrated higher PASI 75 response rates at week 12 compared with guselkumab and ustekinumab (66.7% vs. 28.1% vs. 16.7%,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.010). In the secondary failure subgroup, ixekizumab showed a numerical advantage in PASI 75 response at all time points that did not reach statistical significance. In the primary failure subgroup, the difference in effectiveness between ixekizumab and guselkumab did not reach statistical significance in the limited sample of this study. Adverse event rates were 28.6%, 12.5%, and 33.3% for ixekizumab, guselkumab, and ustekinumab groups, respectively, with no significant between-group differences (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.281). All adverse events were mild and did not require treatment discontinuation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients with moderate-to-severe plaque psoriasis who fail secukinumab, switching to ixekizumab may offer advantages in short- to mid-term effectiveness, particularly in those with secondary failure. Guselkumab offers gradual but sustained improvement. All three agents demonstrate favorable safety profiles. The choice of switching strategy should integrate failure type, patient preference, and drug-specific characteristics.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1866311","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T05:38:10Z","timestamp":1783316290000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness and safety of switching biologics after secukinumab treatment failure in moderate-to-severe plaque psoriasis: a retrospective cohort study"],"prefix":"10.3389","volume":"13","author":[{"given":"Zhongyu","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Dermatology, The First Affiliated Hospital of Chongqing College of Traditional Chinese Medicine","place":["Chongqing, China"]},{"name":"Department of Dermatology, Chongqing Hospital of Traditional Chinese Medicine","place":["Chongqing, China"]},{"name":"Chongqing Key Laboratory of Integrative Dermatology Research","place":["Chongqing, China"]},{"name":"Chongqing Clinical Research Center for Dermatology","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Affiliated Hospital of Chongqing College of Traditional Chinese Medicine","place":["Chongqing, China"]},{"name":"Department of Dermatology, Chongqing Hospital of Traditional Chinese Medicine","place":["Chongqing, China"]},{"name":"Chongqing Key Laboratory of Integrative Dermatology Research","place":["Chongqing, China"]},{"name":"Chongqing Clinical Research Center for Dermatology","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yating","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Affiliated Hospital of Chongqing College of Traditional Chinese Medicine","place":["Chongqing, China"]},{"name":"Department of Dermatology, Chongqing Hospital of Traditional Chinese Medicine","place":["Chongqing, China"]},{"name":"Chongqing Key Laboratory of Integrative Dermatology Research","place":["Chongqing, China"]},{"name":"Chongqing Clinical Research Center for Dermatology","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Affiliated Hospital of Chongqing College of Traditional Chinese Medicine","place":["Chongqing, China"]},{"name":"Department of Dermatology, Chongqing Hospital of Traditional Chinese Medicine","place":["Chongqing, China"]},{"name":"Chongqing Key Laboratory of Integrative Dermatology Research","place":["Chongqing, China"]},{"name":"Chongqing Clinical Research Center for Dermatology","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Affiliated Hospital of Chongqing College of Traditional Chinese Medicine","place":["Chongqing, China"]},{"name":"Department of Dermatology, Chongqing Hospital of Traditional Chinese Medicine","place":["Chongqing, China"]},{"name":"Chongqing Key Laboratory of Integrative Dermatology Research","place":["Chongqing, China"]},{"name":"Chongqing Clinical Research Center for Dermatology","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Zhuo","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Affiliated Hospital of Chongqing College of Traditional Chinese Medicine","place":["Chongqing, China"]},{"name":"Department of Dermatology, Chongqing Hospital of Traditional Chinese Medicine","place":["Chongqing, China"]},{"name":"Chongqing Key Laboratory of Integrative Dermatology Research","place":["Chongqing, China"]},{"name":"Chongqing Clinical Research Center for Dermatology","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangying","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Affiliated Hospital of Chongqing College of Traditional Chinese Medicine","place":["Chongqing, China"]},{"name":"Department of Dermatology, Chongqing Hospital of Traditional Chinese Medicine","place":["Chongqing, China"]},{"name":"Chongqing Key Laboratory of Integrative Dermatology Research","place":["Chongqing, China"]},{"name":"Chongqing Clinical Research Center for Dermatology","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Affiliated Hospital of Chongqing College of Traditional Chinese Medicine","place":["Chongqing, China"]},{"name":"Department of Dermatology, Chongqing Hospital of Traditional Chinese Medicine","place":["Chongqing, China"]},{"name":"Chongqing Key Laboratory of Integrative Dermatology Research","place":["Chongqing, China"]},{"name":"Chongqing Clinical Research Center for Dermatology","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA."},{"key":"B2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00281-015-0539-8","article-title":"Update on psoriasis immunopathogenesis and targeted immunotherapy","volume":"38","author":"Mahil","year":"2016","journal-title":"Semin Immunopathol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1177\/2040622317738910","article-title":"Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis","volume":"9","author":"Frieder","year":"2018","journal-title":"Ther Adv Chronic Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis\u2014results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/bjd.13348","article-title":"Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)","volume":"172","author":"Blauvelt","year":"2015","journal-title":"Br J Dermatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.jaad.2015.05.013","article-title":"Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial","volume":"73","author":"Tha\u00e7i","year":"2015","journal-title":"J Am Acad Dermatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13075-019-1882-2","article-title":"Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data","volume":"21","author":"Deodhar","year":"2019","journal-title":"Arthritis Res Ther."},{"key":"B8","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s40257-021-00640-5","article-title":"Drug survival of interleukin (IL)-17 and IL-23 inhibitors for the treatment of psoriasis: a retrospective multi-country, multicentric cohort study","volume":"23","author":"Torres","year":"2022","journal-title":"Am J Clin Dermatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s13555-024-01328-4","article-title":"Efficacy and safety of risankizumab in patients with psoriasis showing suboptimal response to secukinumab or ixekizumab: results from a phase 3b, open-label, single-arm (aIMM) study","volume":"15","author":"Warren","year":"2025","journal-title":"Dermatol Ther."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1007\/s13555-024-01270-5","article-title":"A 3-year multicentric study on switching from ustekinumab to guselkumab in partial responders with psoriasis\u2014IL PSO (Italian landscape psoriasis)","volume":"14","author":"Valenti","year":"2024","journal-title":"Dermatol Ther."},{"key":"B11","first-page":"573","article-title":"Chinese guidelines for the diagnosis and treatment of psoriasis (2023 edition)","volume":"56","year":"2023","journal-title":"Chin J Dermatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00403-010-1080-1","article-title":"Definition of treatment goals for moderate to severe psoriasis: a European consensus","volume":"303","author":"Mrowietz","year":"2011","journal-title":"Arch Dermatol Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jaad.2018.01.003","article-title":"Efficacy and safety of switching to ixekizumab in secukinumab nonresponders with plaque psoriasis: a multicenter retrospective study of interleukin 17A antagonist therapies","volume":"79","author":"Georgakopoulos","year":"2018","journal-title":"J Am Acad Dermatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"769","DOI":"10.2340\/00015555-3200","article-title":"IL-17A inhibitor switching\u2014efficacy of ixekizumab following secukinumab failure. A single-center experience","volume":"99","author":"Sherman","year":"2019","journal-title":"Acta Derm Venereol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N Engl J Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1056\/NEJMoa1109017","article-title":"Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis","volume":"366","author":"Papp","year":"2012","journal-title":"N Engl J Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.3390\/jpm14121169","article-title":"Efficacy and safety of intra-class switching from ixekizumab to secukinumab in patients with plaque psoriasis: a multicenter retrospective study","volume":"14","author":"Bernardini","year":"2024","journal-title":"Life."},{"key":"B18","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.jaci.2017.07.004","article-title":"Psoriasis pathogenesis and the development of novel targeted immune therapies","volume":"140","author":"Hawkes","year":"2017","journal-title":"J Allergy Clin Immunol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1080\/09546634.2022.2036674","article-title":"Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study","volume":"33","author":"Megna","year":"2022","journal-title":"J Dermatolog Treat."},{"key":"B20","first-page":"319","article-title":"Switching from secukinumab to ustekinumab in psoriasis patients: results from a multicenter experience","volume":"9","author":"Chiricozzi","year":"2019","journal-title":"Dermatol Ther."},{"key":"B21","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial","volume":"76","author":"Reich","year":"2017","journal-title":"J Am Acad Dermatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","article-title":"The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis","volume":"55","author":"Blauvelt","year":"2018","journal-title":"Clin Rev Allergy Immunol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s41927-025-00587-8","article-title":"Comparative effectiveness of cycling versus swapping to IL-17 inhibitors after first TNF inhibitor failure in psoriatic arthritis: a real-world multicenter study","volume":"9","author":"Ariani","year":"2025","journal-title":"BMC Rheumatol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"152671","DOI":"10.1016\/j.semarthrit.2025.152737","article-title":"Biologic switching in psoriatic arthritis: Insights from real-world data and key risk factors","volume":"72","author":"Haddad","year":"2025","journal-title":"Semin Arthritis Rheum."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1007\/s13555-025-01482-3","article-title":"Biologic sequence for the treatment of psoriatic arthritis following nonresponse: a narrative review","volume":"15","author":"Boswell","year":"2025","journal-title":"Dermatol Ther."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1111\/bjd.18851","article-title":"A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial","volume":"182","author":"Blauvelt","year":"2020","journal-title":"Br J Dermatol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1111\/bjd.19509","article-title":"A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial","volume":"184","author":"Blauvelt","year":"2021","journal-title":"Br J Dermatol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1866311\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T05:38:11Z","timestamp":1783316291000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1866311\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":28,"alternative-id":["10.3389\/fmed.2026.1866311"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1866311","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"article-number":"1866311"}}